Select one bioprocess architecture, scale or facility configuration only after product quality, material recovery, equipment fit, finite capacity, consumables, economics, environmental inventory and qualification evidence remain consistent.
Independent company use-case study · life science
Merck KGaA / MilliporeSigmaFive process decisions
Choose one use case. Add authorised plant data. Test capacity, cost and constraints.
Decision brief
One question. One model.
Authorised cell-culture or other feed basis through harvest, filtration, chromatography, concentration, formulation and relevant fill-finish steps, including buffers, single-use assemblies, utilities, holds, waste and released product.
Five practical use cases
Five places to start.
Evaluation scopes for Merck KGaA / MilliporeSigma—not claims of current software use.Compare complete bioprocess architectures
Connect cell culture, harvest, filtration, chromatography, concentration, formulation and fill-finish on one component, time, equipment, consumables and cost basis.
Screen scale-up and facility fit
Translate authorised bench or pilot evidence into mixing, gas-transfer, heat-removal and equipment duties, then test those requirements against customer-supplied facility and utility limits.
Schedule multi-product single-use trains
Sequence bioreactors, harvest and TFF systems, chromatography skids, buffer preparation, assemblies, laboratories and release holds without representing any real customer or MilliporeSigma schedule.
Compare single-use and hybrid lifecycle cases
Evaluate capital, consumables, cleaning, water, energy, waste, accepted output and greenhouse-gas inventory under one declared functional unit and transparent uncertainty ranges.
Connect qualification and supplier evidence
Link requirements, component versions, dossiers, tests, risks, protocols, deviations and acceptance criteria while keeping model review separate from supplier qualification and formal validation.
Action pack
Inputs in. Decisions out.
- Molecule, modality, quality, demand and production-mode basis
- Titer, recovery, flux, capacity, cycle and hold-time evidence
- Bioreactor, filter, chromatography, buffer and facility limits
- Consumables, utilities, waste, cost and lifecycle factors
- End-to-end bioprocess architecture comparison
- Scale-up and facility-fit evidence package
- Finite campaign and consumables plan
- TEA/LCA screen and qualification-evidence register
- Select one customer-authorised process decision.
- Declare modality, quality and system boundaries.
- Import development, equipment and facility evidence.
Evidence and limits
Public evidence only.
- Merck KGaA — Name and brandOfficial name boundary, including MilliporeSigma as the Life Science business name in the United States and Canada and separation from Merck & Co.
- Merck KGaA — Life ScienceOfficial context for the current Life Science structure and Process Solutions portfolio.
- MilliporeSigma — M Lab Collaboration CentersOfficial context for non-GMP process development, optimisation, scale-up and testing across the bioprocess train.
- MilliporeSigma — Biopharma plant designOfficial context for facility design, technology selection, scale-up, technology transfer, installation and qualification.
Guardrail: No Merck KGaA, MilliporeSigma or customer process, product configuration, deployment, integration, facility, schedule, cost, environmental result, qualification or performance value is represented. Technology selection, supplier approval, validation, GxP and regulatory decisions remain within approved company and customer systems.